Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT.
Garderet L, Sbianchi G, Iacobelli S, Blaise D, Byrne JL, Remenyi P, Apperley JF, Touzeau C, Isaksson C, Browne P, Mayer J, Lenhoff S, Gonzalez Muniz S, Parody Porras R, Basak G, Poire X, Trneny M, Nagler A, Michieli M, Tanase A, Koster L, Hayden PJ, Beksac M, Schönland S, Yakoub-Agha I. Garderet L, et al. Among authors: beksac m. Eur J Haematol. 2021 May;106(5):708-715. doi: 10.1111/ejh.13602. Epub 2021 Feb 27. Eur J Haematol. 2021. PMID: 33580608
Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord.
Miniero R, Rocha V, Saracco P, Locatelli F, Brichard B, Nagler A, Roberts I, Yaniv I, Beksac M, Bernaudin F, Gluckman E. Miniero R, et al. Among authors: beksac m. Bone Marrow Transplant. 1998 Jul;22 Suppl 1:S78-9. Bone Marrow Transplant. 1998. PMID: 9715898 Clinical Trial.
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Beksac M, et al. Eur J Haematol. 2011 Jan;86(1):16-22. doi: 10.1111/j.1600-0609.2010.01524.x. Epub 2010 Nov 22. Eur J Haematol. 2011. PMID: 20942865 Clinical Trial.
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Björkstrand B, et al. Among authors: beksac m. J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. J Clin Oncol. 2011. PMID: 21730266
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee. Gahrton G, et al. Among authors: beksac m. Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12. Blood. 2013. PMID: 23482933 Free article. Clinical Trial.
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Iacobelli S, et al. Among authors: beksac m. Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621805 Clinical Trial.
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. San-Miguel JF, et al. Among authors: beksac m. Lancet Haematol. 2016 Nov;3(11):e506-e515. doi: 10.1016/S2352-3026(16)30147-8. Epub 2016 Oct 14. Lancet Haematol. 2016. PMID: 27751707 Clinical Trial.
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A. Raje NS, et al. Among authors: beksac m. Br J Haematol. 2017 Mar;176(5):783-795. doi: 10.1111/bjh.14483. Epub 2016 Dec 22. Br J Haematol. 2017. PMID: 28005265 Free article. Clinical Trial.
468 results